Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis.

@article{Xin2019PrognosticIO,
  title={Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis.},
  author={Yanguo Xin and Wenyu Hu and Xin Chen and Jian Hu and Yingxian Sun and Yinan Zhao},
  journal={Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese},
  year={2019}
}
  • Yanguo Xin, Wenyu Hu, Yinan Zhao
  • Published 8 February 2019
  • Medicine, Biology
  • Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
View on PubMed
doi.org
12 Citations

12 Citations

Light-Chain Cardiac Amyloidosis: A Case Report and Review of the Literature
TLDR
Early diagnosis by cardiac imaging and etiology-oriented treatment are of importance to improve prognosis of AL cardiac amyloidosis.
Transthyretin cardiac amyloidosis in aortic stenosis: prevalence, diagnostic challenges and clinical implications.
Aortic valve intervention for aortic stenosis and cardiac amyloidosis: a systematic review and meta-analysis.
TLDR
An AV intervention is possibly not futile in CA-AS and should not be denied to patients with this condition, according to a meta-analysis of outcomes after aortic valve (AV) intervention.
Correlation of Quantitative 99mTc DPD Scintigraphy With Echocardiographic Alterations in Left Atrial Parameters in Transthyretin Amyloidosis.
JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis.
TLDR
This document is an English version of JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis reported at the 84th Annual Scientific Meeting of Japanese Circulation Society performed in 2020.
Evidence-Based PET for Cardiac Diseases
This chapter summarizes 15 meta-analyses published in the literature on the use of PET for cardiac diseases, with the majority (n = 8) concerning the diagnosis of coronary artery disease (CAD) using…
Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis
Percutaneous mitral valve repair (PMVR) is a therapeutic option for severe mitral regurgitation (MR) in patients with heart failure due to differential aetiologies. However, only little is known…
Heart Failure: From novel pharmaceutical therapies to circulation support systems.
  • D. Tousoulis
  • Biology
    Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
  • 2021
Heart Failure: From novel pharmaceutical therapies to circulation support systems.
  • D. Tousoulis
  • Biology
    Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
  • 2021
Typical and atypical imaging features of cardiac amyloidosis.
...
...

References

SHOWING 1-10 OF 46 REFERENCES
Clinical and echocardiographic characteristics for differentiating between transthyretin-related and light-chain cardiac amyloidoses
TLDR
Clinical characteristics of patients with biopsy-proven cardiac amyloidosis were investigated and the BNP-LVMI ratio, as well as age and sex, may be useful parameters for distinguishing TTR from AL cardiac ameloidosis.
Identification of prognostic markers in transthyretin and AL cardiac amyloidosis*
  • T. Damy, A. Jaccard, D. Mohty
  • Medicine
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • 2016
TLDR
High NT-proBNP, low cardiac output, and pericardial effusion at the time of screening should prompt physician to refer the patients to amyloidosis referral center, and NT- ProBNP is a strong prognosticator in the three types of cardiac amyloidsosis.
Subtype‐Specific Interactions and Prognosis in Cardiac Amyloidosis
TLDR
Clinical, morphological, electrical, and biomarker data do not significantly interact with amyloid subtype in its association with mortality, despite the fact that the prognosis in each subtype differs greatly, which suggests an additional factor or factors contributing to poorer outcomes in AL amyloids.
Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center.
TLDR
Patients with transthyretin cardiac amyloidosis V122I patients presented to a tertiary academic medical center at a younger age than SCA patients but had higher levels of cardiac dysfunction, despite genetic screening availability.
Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis
TLDR
In patients with CA, worsening LV function correlated with increasing wall thickness regardless of pathogenesis, and patients with ATTRwt had a statistically greater wall thickness but lesser mortality than those with AL amyloidosis, despite very similar degrees of LS impairment.
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).
Prognostic implication of relative regional strain ratio in cardiac amyloidosis
TLDR
High RRSR is adversely prognostic in patients with cardiac amyloid, and this novel tool is both diagnostic and prognostic and may have implications in management and suitability for treatment.
The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.
TLDR
It should be suspected in all patients with heart failure who have wall thickening on echo, normal chamber sizes, low EKG voltages and evidence suggesting a multisystem disease, and most frequently patients had features of multiorgan dysfunction; heavy proteinuria and features of mal absorption predominating in this respect.
...
...